Vol 2014, No 12 (2014)

Table of Contents

Licensing

Pfizer Pays Merck KGaA US$850 M Upfront to Compete in Immuno-Oncology Abstract
Heather Cartwright

Mergers & Acquisitions

Allergan Rebuffs Valeant and Agrees to US$66 B Actavis Deal Abstract
Heather Cartwright
Otsuka Continues Overseas Expansion with US$3.5 B Avanir Buyout Abstract
Heather Cartwright
Merck & Co. Agrees to Buy Cubist in US$9.5 B Deal to Strengthen its Acute Care Portfolio Abstract
Heather Cartwright


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.